Colin McCall

Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

Show full CV Hide full CV

Career

Since 2020	Partner, Taylor Wessing
2016 - 2020	Senior Counsel, Taylor Wessing
2010 - 2016	Senior Associate, Taylor Wessing

2006 - 2010	Associate,Taylor Wessing
2004 - 2006	Associate, Linklaters
2002 - 2004	Trainee, Linklaters

More Less

Education

2013	MSc Energy Environmental Technology and Economics, London City University
2005	Diploma in Intellectual Property Law and Practice, Bristol University
2004	Admitted as a lawyer, England, Wales

2000	Graduate Diploma in Law, Nottingham Law School
1998	BSc in Cell Biology, Durham University

More Less

Additional languages

English

Expertise

Sectors Life sciences & healthcare Real estate Medical devices Real estate life sciences & healthcare

Experience

Ceres Power on numerous strategic collaborations	Including on its transformational licensing and equity investment deals done with Weichai Power in China and with Robert Bosch GmbH in respect of Ceres Power's solid oxide fuel cell technology.
Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm	Advised Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.
Oxford BioMedica on its transformational deal with Novartis re: Kymriah	Oxford BioMedica on various commercial and licensing deals including its collaboration, development and licence agreement with Novartis in respect of Kymriah, which became the first gene therapy ever to receive FDA approval and on its manufacturing agreements for clinical and commercial supply of Kymriah to Novartis.

Apotex's EUR74m sale of subsidiaries to Aurobindo	Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.
Shire Pharmaceuticals on a global review of its distribution and supply arrangements	Shire Pharmaceuticals on its review and subsequent improvement of its contractual arrangements for distribution and supply of its global portfolio of products in order to make Shire acquisition ready.
Jet Airways	Jet Airways in relation to High Court patent proceedings brought against it by Virgin Atlantic.

More Less

Awards

Legal 500 UK 2023	Life Sciences and Healthcare - "Stand out partner for me has been Colin McCall, who has single-handedly helped us get a hugely complex licensing deal over the line. His understanding of the detail of licence terms and the complex background to the development of the IP was instrumental to making all the parties make appropriate concessions to getting a deal over the line, and avoiding lengthy stand offs and threats of walking away."
Legal 500 UK 2022	Biotechnology: "Colin McCall has provided excellent service – he makes sure to understand the client’s needs and reliably delivers high-quality work within the agreed timelines and budgets. He is an excellent communicator, very personable and a pleasure to deal with."
Legal 500 UK 2022	Intellectual Property
Legal 500 UK 2022	IP - contentious and non-contentious